Key result
AHA COVID-19 CVD Registry rapidly enrolls over 4,000 hospitalized patients to track clinical and biomarker data.
Why the study?
In response to the COVID-19 pandemic, there was an urgent need to rapidly develop a resource for shared learning, quality improvement, and research to understand the impact of COVID-19 on cardiovascular disease.
Observational (n=4,000)
Yes
The AHA COVID-19 CVD Registry was rapidly developed to collect data on hospitalized COVID-19 patients to evaluate outcomes and inform best practices.
Answers are grounded in this paper and cite their sources.
Provides hospitals national benchmarks for COVID-19 outcomes; extends prior registry infrastructure to pandemic CVD research.
BACKGROUND: In response to the public health emergency created by the coronavirus disease 2019 (COVID-19) pandemic, American Heart Association volunteers and staff aimed to rapidly develop and launch a resource for the medical and research community to expedite scientific advancement through shared learning, quality improvement, and research. In <4 weeks after it was first announced on April 3, 2020, AHA's COVID-19 CVD Registry powered by Get With The Guidelines received its first clinical records. METHODS AND RESULTS: Participating hospitals are enrolling consecutive hospitalized patients with active COVID-19 disease, regardless of CVD status. This hospital quality improvement program will allow participating hospitals and health systems to evaluate patient-level data including mortality rates, intensive care unit bed days, and ventilator days from individual review of electronic medical records of sequential adult patients with active COVID-19 infection. Participating sites can leverage these data for onsite, rapid quality improvement, and benchmarking versus other institutions. After 9 weeks, >130 sites have enrolled in the program and >4000 records have been abstracted in the national dataset. Additionally, the aggregate dataset will be a valuable data resource for the medical research community. CONCLUSIONS: The AHA COVID-19 CVD Registry will support greater understanding of the impact of COVID-19 on cardiovascular disease and will inform best practices for evaluation and management of patients with COVID-19.
No takes yet. Share an insight, caveat, or question.
Alger et al. (2020) conducted an observational in COVID-19 (n=4,000). The American Heart Association COVID-19 CVD Registry was rapidly established and successfully enrolled over 4,000 hospitalized adult patients to collect comprehensive clinical and biomarker data.
Synapse has enriched 10 related papers. Consider them for comparative context: